Is Wegovy Still in Short Supply in the UK?

You went to reorder and your dose strength was out of stock

This scenario played out for thousands of UK patients in 2023 and 2024, and it still catches people off guard today. The shortage hit higher doses hardest at first (1.7mg and 2.4mg pens were the last to return to reliable availability) because Novo Nordisk initially prioritised starter doses to bring new patients onto treatment. By mid-2025 the picture had shifted, and most strengths were reaching most UK pharmacies regularly. But stock is managed dose by dose, and a regional gap at your particular pharmacy does not always mean a national shortage.

The practical first step is to contact your prescribing pharmacy directly rather than assuming Wegovy is gone. Stock can move within days. The current Wegovy supply situation in the UK is something our team monitors closely, and our GPhC-registered prescribers can advise on your specific dose at consultation. If a pen is genuinely unavailable, the clinical guidance is usually to hold your current dose rather than miss weeks of treatment without advice, but that call belongs to your prescriber, not a website.

One practical note worth passing on: patients who keep their pen in the fridge door rather than the back of the shelf tend to notice immediately if a delivery hasn't arrived, which matters more when stock is tight. If you are thinking about ordering further ahead to avoid this situation, you can read about getting a Wegovy 3 month supply and whether that approach suits your circumstances.

Why the Wegovy shortage happened, and whether it is over

Wegovy's supply problems were not unique to the UK. Global demand for semaglutide after its weight-management licences outpaced manufacturing capacity across every market where it launched. In the UK, the MHRA listed Wegovy as a medicine in shortage, and NHS England issued guidance asking prescribers not to start new patients until supply stabilised. That restriction was eventually lifted as Novo Nordisk brought additional production lines online.

The supply issues affecting Wegovy have eased significantly, but the word "over" overstates things. Manufacturer forecasts are not publicly guaranteed, demand continues to grow (particularly as the NHS rolls out access to more patient groups) and the approval of the 7.2mg single-dose pen in April 2026 added a new strength to the supply chain. Realistically, occasional gaps at the level of individual strengths or individual pharmacies should be expected for the foreseeable future. What has changed is that a gap now usually means days, not months.

For context on how long a standard supply period covers, a one-month supply of Wegovy means four weekly injections from a single pen, so even a short stock disruption can affect continuity of treatment if you do not reorder promptly.

What a shortage does not justify, and the counterfeit risk

When a familiar medicine becomes hard to find, some people look outside the regulated supply chain. For Wegovy, that is a serious risk. The MHRA has warned publicly and repeatedly about fake weight-loss pens sold via social media and unregistered websites, counterfeit pens have been found to contain insulin rather than semaglutide, with real harm to patients who received them. Large seizures of fake pens have taken place across the UK, and enforcement action escalated significantly through 2025.

The safe route is a prescription from a regulated prescriber, dispensed by a pharmacy you can verify on the GPhC pharmacy register. Red flags include sellers offering these medicines without a prescription, prices far below the market range, and unverifiable UK addresses. A shortage does not change what is legal or what is safe, it just makes the temptation more understandable. Report any suspect seller via the MHRA's Yellow Card scheme.

If you are weighing up Wegovy alongside other licensed options, the weight-loss treatment overview sets out what is currently available through regulated UK prescribing.

How semaglutide's expanding licence affects the supply picture

Semaglutide demand is not static. As of 2026, Wegovy holds UK authorisations for weight management, cardiovascular risk reduction in eligible adults, and (from July 2026) a conditional licence for a form of fatty liver disease (MASH). That last indication was confirmed by the MHRA on 3 July 2026. More approved indications mean more patients who may legitimately be prescribed the medicine, which adds pressure to a supply chain that is still scaling. NHS England has also been phasing in Wegovy access through specialist weight management services under NICE technology appraisal TA875, and NHS waiting lists for those services remain long in most areas.

Private prescribing, through a GPhC-registered pharmacy with its own regulated supply, is how many patients access Wegovy without joining an NHS waiting list, provided they meet the clinical criteria and a prescriber confirms suitability. That route is not immune to supply pressures, but a pharmacy with direct supplier relationships is generally better placed to manage stock than a general high-street chemist. Some patients also ask whether you can take Wegovy for a short time rather than committing to ongoing treatment, which is worth understanding before you decide on your approach. More on how semaglutide works is available if you want to understand the medicine itself before deciding whether it is right for you.